Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x

SPECTRAL MEDICAL Aktie

>SPECTRAL MED Performance
1 Woche: 0%
1 Monat: +4,8%
3 Monate: +20,6%
6 Monate: +70,3%
1 Jahr: +75,8%
laufendes Jahr: +70,3%
>SPECTRAL MEDICAL Aktie
Name:  SPECTRAL MEDICAL
Land:  Kanada
Sektor:  Gesundheit
ISIN/ Wkn:  CA8475771033 / A12HJ9
Symbol/ Ticker:  SD4 (Frankfurt)
Kürzel:  FRA:SD4, ETR:SD4, SD4:GR
Index:  -
Webseite:  https://spectraldx.com/
Marktkapitalisierung:  159.51 Mio. EUR
Umsatz:  1.9 Mio. EUR
EBITDA:  -11.63 Mio. EUR
Gewinn je Aktie:  -0.043 EUR
Schulden:  13.23 Mio. EUR
Liquide Mittel:  1.45 Mio. EUR
Umsatz-/ Gewinnwachstum:  -14.4% / -
KGV/ KGV lG:  - / -
KUV/ KBV/ PEG:  110.54 / - / -
Gewinnm./ Eigenkapitalr.:  - / -
Dividende je Aktie:  -
Dividendenrendite/ -schätzung:  - / -
Insiderhandel:  -
Suchwörter:  SPECTRAL MEDICAL, SPECTRAL MED
Letzte Datenerhebung:  06.07.25
>SPECTRAL MED Eigentümer
Aktien: 285.12 Mio. St.
f.h. Aktien: 199.3 Mio. St.
Insider Eigner: 17.97%
Instit. Eigner: 12.74%
Leerverk. Aktien: -
>SPECTRAL MED Peer Group

 
04.07.25 - 21:12
Spectral Medical Inc. Announces Filing of Base Shelf Prospectus (GlobeNewswire EN)
 
TORONTO, July 04, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced that it has filed a preliminary short form base shelf prospectus with the securities regulatory authorities in each of the provinces of Canada, except Québec (the “Securities Regulators”)....
06.06.25 - 17:03
Spectral Medical Inc. Announces Results of Annual Meeting of Shareholders (GlobeNewswire EN)
 
TORONTO, June 06, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. ("Spectral" or the "Company") (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced the results of its Annual Meeting of shareholders (the "Shareholders") held yesterday on June 5, 2025 (the "Meeting"). The Company confirms that all resolutions put forward in the Management Information Circular dated April 17, 2025 (the "Circular") to its Shareholders were approved....
16.05.25 - 14:03
Spectral Medical to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference (GlobeNewswire EN)
 
TORONTO, May 16, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced that management will participate in a fireside chat at the 3rd Annual H.C. Wainwright BioConnect Investor Conference, on Tuesday, May 20, 2025 at 11:30 a.m. ET at the Nasdaq headquarters in New York City, New York....
09.05.25 - 17:51
Spectral Medical reports Q1 results (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
09.05.25 - 13:33
Spectral Medical Announces First Quarter and Provides Corporate Update (GlobeNewswire EN)
 
TORONTO, May 09, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced its financial results for the first quarter and provided a corporate update....
16.04.25 - 13:03
Spectral Medical Completes Tigris Trial Enrollment (GlobeNewswire EN)
 
TORONTO, April 16, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced the completion of full enrollment in the Company's Tigris trial, a Phase 3 follow-on study evaluating the use of Polymyxin B Hemoperfusion (“PMX”) in a randomized controlled trial of adults treated for endotoxic septic shock....
02.12.24 - 14:03
Spectral Medical Provides November Tigris Trial Update (GlobeNewswire EN)
 
•  136 patients enrolled...
08.11.24 - 14:03
Spectral Medical Announces Third Quarter Results and Provides Corporate Update (GlobeNewswire EN)
 
Tigris Trial Enrollment at 135 PatientsStrengthened Balance Sheet with Expected Funds to Complete Tigris Trial Enrollment...
04.11.24 - 14:03
Spectral Medical Provides October Tigris Trial Update (GlobeNewswire EN)
 
• 135 patients enrolled...
03.09.24 - 13:33
Spectral Medical Provides August Tigris Trial Update (GlobeNewswire EN)
 
Management provides view on recently announced Vantive-Carlyle Group transaction Management provides view on recently announced Vantive-Carlyle Group transaction...
09.08.24 - 20:21
Spectral Medical reports Q2 results (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
09.08.24 - 14:03
Spectral Medical Announces Second Quarter Results and Provides Corporate Update (GlobeNewswire EN)
 
Tigris Trial Enrollment Reaches 126 Patients...
01.08.24 - 14:06
Spectral Medical Provides July Tigris Trial Update (GlobeNewswire EN)
 
• 125 patients enrolled• Record July patient enrollment to start the second half of 2024 ...
11.07.24 - 22:03
Spectral Medical Inc. Announces Change to Auditor (GlobeNewswire EN)
 
TORONTO, July 11, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. ("Spectral" or the "Company") (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced that MNP LLP (“MNP”) have today been appointed as the auditors of the Company following the decision by PricewaterhouseCoopers LLP (“PwC”) to resign as the auditor of Spectral (the “Effective Date”). The resignation of PwC as the auditor of Spectral and the appointment of MNP as auditor of Spectral were considered and approved by the Finance & Audit Committee and the board of directors....
02.07.24 - 13:33
Spectral Medical Provides June Tigris Trial Update (GlobeNewswire EN)
 
TORONTO, July 02, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today provided an update on the Company's Tigris trial, a Phase 3 follow-on study evaluating the use of Polymyxin B Hemoperfusion (“PMX”) in a randomized controlled trial of adults treated for endotoxemia and septic shock....
07.06.24 - 22:21
Spectral Medical Inc. Announces Results of Annual Meeting of Shareholders (GlobeNewswire EN)
 
TORONTO, June 07, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. ("Spectral" or the "Company") (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced the results of its Annual Meeting of shareholders (the "Shareholders") held earlier today (the "Meeting"). The Company confirms that all resolutions put forward in the Management Information Circular dated April 19, 2024 (the "Circular") to its Shareholders were approved....
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Männer sind wie Luft, zwar versaut, aber unentbehrlich. - Michelle Pfeiffer
Partner:    >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!